Changes in tumor cells that lead to metastasis

The researchers detected CTCs undergoing cell division in a breast cancer patient on systemic treatment. Thus, CTCs have been demonstrated both to be able to adapt to hostile microenvironments as blood, and to resist treatment and divide and proliferate in other organs and tissues, causing metastasis. So far, this behavior had not been observed in this type of microenvironments.

The results of this study were described in the article "Biodynamics of Circulating Tumor Cell, Tumor Microenvironment and Metastasis," published in the journals Cancer Biology & Therapy, Clinical Translational Oncoly y Annals of Oncology. The researchers found that breast cancer patients with circulating tumor cells (CTCs) at baseline tend to develop metastasis and have shorter disease-free survival after treatment. Thus, detecting CTCs during and after treatment allows physicians to identify which patients are responding favorably to chemotherapy. Consequently, patients with CTCs while receiving chemotherapy have shorter disease-free survival and lower overall survival rates. This is due to the fact that these cells are resistant to conventional treatments performed according to the genetic characteristics of the tumor. Therefore, CTCs can survive chemotherapy and produce metastasis to other organs.

More Efficient Individualized Treatments

University of Granada professor José Antonio Lorente -GENYO manager director and coordinator of the research group- affirms that the study of Circulating Tumor Cells (CTCs) is crucial "not only because they may be responsible for the development of metastasis, but also because they have genetic characteristics different to those found in the primary tumor and in metastatic cells. Such characteristics make these very aggressive cells resistant to the immunologic system and to the therapeutic agents generally used in cancer patients." Most of these treatments are targeted against proliferating tumor cells. Conversely, CTCs are found in a "dormant" phase, i.e. in a "non-proliferation" phase.

As these cells may indicate negative response to treatment, if they were isolated and genetically characterized, patients could be classified according to their chances of relapse, which would allow individualized follow-up.

The research group "Biodynamics of Circulating Tumor Cell, Tumor Microenvironment and Metastasis" is composed of Dr. María José Serrano Fernández, José Luis García Puche, Pedro Sánchez Rovira, Juan Carlos Álvarez, Lucas González Herrera, Laura Vera Rodríguez, José Javier López Caballero and José Antonio Lorente. This group has already registered a patent associated with the results of this research. This international project counts on the participation of Roche Pharma, Pangaea and Dr. Íñigo Martínez Zubiauprofessor, at the University of Tromso (Norway)